Theranostic Capture Agents for PSMA Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for prostate cancer lack effective markers and methods for precise targeting and detection of prostate-specific membrane antigen (PSMA), limiting the accuracy and effectiveness of prostate cancer diagnosis and treatment.
Innovation Solution
Development of theranostic capture agents comprising ligands specifically binding to distinct epitopes of PSMA, which can be loaded with detectable or therapeutic moieties, enabling both diagnostic imaging and therapeutic delivery to prostate cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic and therapeutic approaches are used for prostate cancer, then general treatment methods are applied, but specificity and precision in targeting PSMA are insufficient
Solution Approach 1:
The capture agent is segmented into multiple functional components: multiple ligands (e.g., peptides or antibodies) that bind to different epitopes of PSMA, linkers that connect the ligands, and loading sites for detectable or therapeutic moieties. This segmentation allows each component to perform its specific function while contributing to the overall precision and versatility of the theranostic agent.
Solution Approach 2:
The capture agent is designed with multi-functionality to serve both diagnostic and therapeutic purposes. By incorporating multiple ligands that bind to different epitopes of PSMA, the agent can detect PSMA with high precision while simultaneously providing targeted therapy. The universal design allows a single agent to fulfill multiple roles, improving both detection accuracy and targeting specificity.
2Reliability
If single-epitope binding agents are used, then simplicity is maintained, but binding affinity and specificity to PSMA are limited
Solution Approach 1:
Multiple ligands with different specificities for PSMA epitopes are merged into a single capture agent structure. This combining of multiple binding elements enhances the overall binding affinity and reliability of PSMA recognition, while the linked structure maintains reasonable complexity for practical application.
Solution Approach 2:
The capture agent employs a composite structure comprising multiple ligand types (e.g., peptide ligands and/or antibody ligands) connected through linkers. This composite design leverages the strengths of different ligand classes to achieve high binding affinity and specificity for PSMA, while the modular architecture manages structural complexity.
3Ease of manufacture
If separate diagnostic and therapeutic agents are used, then each agent can be optimized for its specific function, but coordination and precision in targeting the same PSMA are reduced
Solution Approach 1:
The capture agent is designed as a universal platform that integrates both diagnostic and therapeutic functions. By incorporating multiple ligands that bind to different epitopes of PSMA within a single agent structure, the invention ensures that both diagnostic imaging and therapeutic delivery target the same PSMA molecules with consistent precision, eliminating the coordination problems associated with using separate agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The theranostic capture agents provide high specificity and affinity for PSMA, enabling precise detection and targeted therapy for prostate cancer, improving diagnostic accuracy and treatment outcomes.
Implementation Method 1
the ligands specifically bind to one of two or more distinct epitopes of a target that are in different locations on the target
Data Source
AI summary
Disclosed are compounds, compositions, and methods involving theranostic capture agent for a target where the capture agent is (a) a precursor that can be loaded with a detectable moiety, a therapeutic moiety, or both, (b) loaded with a detectable moiety, (c) loaded with a therapeutic moiety, or (d) loaded with both a detectable moiety and a therapeutic moiety. Also disclosed are stable peptide-based PSMA capture agents and methods of use as detection agents.